bioAffinity Technologies Files 8-K
Ticker: BIAFW · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1712762
| Field | Detail |
|---|---|
| Company | Bioaffinity Technologies, INC. (BIAFW) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.007 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K with updated financials - check for details.
AI Summary
On October 16, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates or disclosures related to the company's financial health and operations. No specific new events or material changes were detailed in the provided excerpt.
Why It Matters
This filing indicates bioAffinity Technologies, Inc. is providing updated financial statements and exhibits, which could contain important information for investors regarding the company's financial status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material adverse events.
Key Numbers
- 001-41463 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-5211056 — EIN (Company's Employer Identification Number.)
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- October 16, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41463 (commission_file_number) — SEC File Number
- 46-5211056 (ein) — I.R.S. Employer Identification Number
- 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217 (address) — Principal executive offices
FAQ
What specific financial statements or exhibits are being filed with this 8-K?
The filing indicates 'Financial Statements and Exhibits' are being provided, but the specific details of these documents are not included in the provided excerpt.
Does this 8-K report any new material events for bioAffinity Technologies, Inc.?
The filing lists 'Other Events' and 'Financial Statements and Exhibits' as items, but the excerpt does not detail any specific new material events beyond the filing of these documents.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 16, 2025.
Where is bioAffinity Technologies, Inc. headquartered?
The company's principal executive offices are located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
What is the SIC code for bioAffinity Technologies, Inc.?
The Standard Industrial Classification (SIC) code for bioAffinity Technologies, Inc. is 8731, which falls under SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-10-16 09:15:51
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 18KB
- ex99-1_002.jpg (GRAPHIC) — 10KB
- 0001493152-25-018267.txt ( ) — 310KB
- biafw-20251016.xsd (EX-101.SCH) — 4KB
- biafw-20251016_def.xml (EX-101.DEF) — 26KB
- biafw-20251016_lab.xml (EX-101.LAB) — 36KB
- biafw-20251016_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 16, 2025 BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -3-